VIRX News and Press, Viracta Therapeutics Inc. From 07/21/21

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors Third combination trial with nanatinostat and valganciclovir broadens scope beyond EBV+ lymphoproliferative disorders Trial initiation expe...

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team PR Newswire SAN DIEGO , July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncolog...

Viracta Therapeutics ([[VIRX]]) was added to the Russell 2000, Russell 3000 and the Russell Microcap indexes, as part of the 2021 Russell indexes annual reconstitution, effective June 28, when the U.S. market opens. The company said membership in the U.S. all-cap Russ...

Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes PR Newswire SAN DIEGO , June 28, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated...

Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma Now open for enrollment, NAVAL-1 is a multicenter basket trial with an adaptive Simon 2-stage design PR Newswire ...

Viracta Therapeutics (VIRX) has filed for a $200M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.Viracta shares are down 0.3% to $10.35 in after-hours trading. For further details see: Viracta Therapeutics ...

Viracta Therapeutics to Host Key Opinion Leader Webinar Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET PR Newswire...

Viracta Therapeutics (VIRX): Q1 GAAP EPS of -$5.22 misses by $5.24.Cash and cash equivalents of $129.2M.Press Release For further details see: Viracta Therapeutics EPS misses by $5.24

Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma is on track to be initiated in Q2 2021 NAVAL-1 trial design to be feat...

Adverum Bio cut to market perform at SVB LeerinkAdverum Biotechnologies (ADVM) has gained ~3.8% in the premarket despite a downgrade by   SVB Leerink to market perform from outperform. The price target of $5.00 per share implies ~28.2% upside to the last close.The cancella...